The University of Kansas Cancer Center (KUCC) is a matrix cancer center that includes: the University of Kansas Medical Center campuses in Kansas City and Wichita, the University of Kansas-Lawrence, and the Stowers Institute for Medical Research (via consortium agreement). In 2010, 143 members of KUCC accounted for $11.4 million of NCI funding and a total of $55.1 million in overall cancer-related funding. KUCC is led by Roy A. Jensen, M.D. who is supported by a strong, nationally recognized leadership team. Over the last seven years substantial progress has been made securing institutional commitment, recruiting key leadership positions, building nationally significant research programs, developing our clinical research program, improving and expanding our facilities, and creating transdisciplinary and collaborative interactions. With input from our External Advisory Board, we have established three goals for KUCC that will insure we make a national impact in the fight against cancer: Goal 1: Become the leading academic institution for transforming discoveries from the laboratory into new anticancer drug therapies. Goal 2: Provide the optimal environment for basic, translational, clinical, and population-based research in oncology by developing and fostering a collaborative, collegial, and dynamic culture of scientific inquiry. Goal 3: Be a nationally recognized leader in partnering with community oncologists and other key stakeholders to develop, promote, and foster the adoption and implementation of research-based cancer prevention, diagnosis, treatment, control, and survivorship practices throughout our service area. To accomplish these goals KUCC has four research programs including: Cancer Biology, Cancer Control and Population Health, Cancer Prevention, and Drug Discovery, Delivery and Experimental Therapeutics. In addition, the Cancer Center supports four shared resources: Biostatistics and Informatics, Lead Development and Optimization, Biospecimen, and Clinical Trials Management.

Public Health Relevance

KUCC aims to leverage unique regional scientific assets to build a nationally significant cancer research center that will become a leading institution for transforming discoveries in the laboratory into new therapeutic approaches. We hope to establish an NCI-designated cancer center to meet the needs of the more than five million Americans who live within the 120,000 square miles of our catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-03
Application #
8702103
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2012-07-11
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
$1,510,000
Indirect Cost
$510,000
Name
University of Kansas
Department
Pathology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Gonzalez-Mercado, Velda J; Fridley, Brooke L; Saligan, Leorey N (2018) Sestrin family of genes and their role in cancer-related fatigue. Support Care Cancer 26:2071-2074
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Lea, Wendy A; Parnell, Stephen C; Wallace, Darren P et al. (2018) Human-Specific Abnormal Alternative Splicing of Wild-Type PKD1 Induces Premature Termination of Polycystin-1. J Am Soc Nephrol 29:2482-2492
Hirst, Jeff; Pathak, Harsh B; Hyter, Stephen et al. (2018) Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties. Cancer Res 78:4370-4385
Trinca, Gloria M; Goodman, Merit L; Papachristou, Evangelia K et al. (2018) O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer. Horm Cancer 9:12-21
Subramaniam, Dharmalingam; Kaushik, Gaurav; Dandawate, Prasad et al. (2018) Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer. Curr Med Chem 25:2585-2594
Beadnell, Thomas C; Scheid, Adam D; Vivian, Carolyn J et al. (2018) Roles of the mitochondrial genetics in cancer metastasis: not to be ignored any longer. Cancer Metastasis Rev :
Li, Linda Xiaoyan; Zhou, Julie Xia; Calvet, James P et al. (2018) Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death Dis 9:326
Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:

Showing the most recent 10 out of 177 publications